Targacept (TRGT -32.1%) catches the eye of analysts a bit late after the firm bombs with Phase...
Targacept (TRGT -32.1%) catches the eye of analysts a bit late after the firm bombs with Phase III clinical results for its antidepressant drug-candidate TC-5214. Leerink Swann downgrades shares to Market Perform from Outperform, while Global Hunter takes its rating down to Neutral from Accumulate.
From other sites
at MarketWatch.com (Dec 17, 2013)
at MarketWatch.com (Dec 16, 2013)
at MarketWatch.com (Sep 18, 2012)
at MarketWatch.com (Mar 20, 2012)
at MarketWatch.com (Dec 20, 2011)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs